Evaluating a strategy of PAH therapy pre-treatment in patients with atrial septal defects and pulmonary arterial hypertension to permit safe repair ( “treat-and-repair”)

Pulmonary arterial hypertension (PAH) associated with congenital heart disease (PAH-CHD) remains a major cause of morbidity and mortality in the growing adult congenital heart disease population. In the face of sustained progress, fewer patients are presenting with severe pulmonary vascular disease (PVD) with reversal of the shunt, cyanosis and multi-organ involvement, characteristic of Eisenmenger syndrome [1]. By contrast, patients with predominant systemic-pulmonary shunts and varying degrees of PAH are more commonly encountered.

Source: International Journal of Cardiology - May 19, 2019 Category: Cardiology Authors: Andrew Constantine, Konstantinos Dimopoulos Tags: Editorial Source Type: research